{
    "title": "Breast cancer breakthrough boost at AstraZeneca: Enhertu drug shows positive results in late-stage trial",
    "url": "https://www.dailymail.co.uk/money/markets/article-10536029/Astrazeneca-boosted-positive-trials-breast-cancer-drug-Enhertu.html",
    "date": "2022-02-21",
    "keywords": [
        "cancer",
        "breast",
        "drug",
        "share",
        "cent",
        "fund",
        "news",
        "trial",
        "improvement",
        "uk",
        "research",
        "capital",
        "money",
        "platform",
        "companys",
        "investment",
        "account",
        "fee",
        "boost",
        "yesterdaya",
        "latestage",
        "ftse",
        "cancermetastatic",
        "stage",
        "iv",
        "body",
        "liver",
        "brain",
        "cancerthis",
        "type",
        "chemotherapy",
        "longerbreast",
        "world",
        "year",
        "day",
        "astrazeneca",
        "firm",
        "kind",
        "benefit",
        "clinique",
        "beauty",
        "breach",
        "interest",
        "evidence",
        "treasury",
        "article",
        "diy",
        "executive",
        "vice",
        "president",
        "oncology",
        "development",
        "broker",
        "liberum",
        "multibillion",
        "dollar",
        "opportunity",
        "enhertu",
        "treatment",
        "cancerinvestment",
        "bank",
        "ubs",
        "data",
        "door",
        "growth",
        "price",
        "risk",
        "isa",
        "trade",
        "month",
        "community",
        "model",
        "affiliate",
        "product",
        "commission",
        "editorial",
        "independence",
        "investing"
    ],
    "category": [
        "money",
        "markets"
    ]
}